Faber and colleagues demonstrate that expression of the pro-apoptotic Bcl-2 family member BIM predicts the capacity of selective kinase inhibitors to induce apoptosis in cancers addicted to EGFR, HER2, PI3K, or BRAF signaling. Evaluating BIM levels in tumor biopsies prior to chemotherapy therefore has the potential to predict which patients are most likely to respond to single-agent kinase inhibitor therapy. For details, please see the article by Faber and colleagues on page 352.